Global pharma major Lupin Limited (Lupin) announced the launch of its Abbreviated New Drug Application of its recently approved drug: Sugammadex Injection in the United States on Friday.Following approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application, the company launched Sugammadex injection, 200 mg/2 mL and 500 mg/5 mL Single-Dose Vial variant in the US, Lupin said in a regulatory filing.Read more: Maharashtra FDA trains guns on overpriced drugsThe firm’s calims its injection to be a bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC (Merck).The release adds that the injection is to be indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.Read more: Piramal Pharma to focus on policy, not Trump tariff tweets: Nandini Piramal
Lupin launches generic Sugammadex injection in US
Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.
140 words~1 min read
